The obesity management market is expected to expand with a CAGR of 5.2% during the forecast period from 2023 to 2033. The overall market value is projected to grow from USD 2,095.6 million in 2023 to USD 3,494.5 million by 2033.
Due to the steep rise in obesity prevalence over the last two decades, the global market is expected to generate significant revenue in the future. The key factors expected to drive the market are:
| Report Attributes or Data Points | Details |
|---|---|
| Global Obesity Management Market Valuation in 2022 | USD 1,994 million |
| Estimated Global Market Share in 2023 | USD 2,095.6 million |
| Forecasted Global Market Size by 2033 | USD 3,494.5 million |
| Projected Global Market Growth Rate from 2023 to 2033 | 5.2% CAGR |
| Historical Market Growth Rate from 2018 to 2022 | 4% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Obesity affects one in every three adults in North America. Obesity causes a slew of chronic diseases, many of which can be avoided with proper weight management. Obese patients should be treated for the initial stage of hypertension by losing weight through lifestyle changes, pharmacological treatment, and/or bariatric surgery, according to the AHA.
The NHS in the United Kingdom has suggested that weight loss programs educate people about the dangers of obesity and assist obese people in losing weight. People are becoming more aware of their physical appearance.
The high cost of surgeries and drugs may be a barrier to obesity management. Weight loss surgery is not reimbursed favorably in developing countries. Because weight management is a time-consuming process, medical payers are hesitant to provide reimbursement.
Furthermore, concerns about the safety of obesity management drugs are cruising clinical trials, with only a few drugs reaching the market. Drug-induced cardiovascular disease or cancer can be caused by certain drug formulations. These incidents have the potential to result in drug recalls.
The FDA, for example, has requested that Eisai withdraw its weight-loss drug Belviq from the market after clinical trials revealed an increased incidence of cancer in users.
Principal Consultant
Geriatric population growth in developed countries, primarily due to improved healthcare leading to increased life expectancy, is driving the market. This is because geriatric people are highly susceptible to gaining noticeable body fat while losing muscle mass and functioning ability. As a result, the geriatric population is a critical segment of the market in both the short and long term.
Aside from that, genetics and medication side effects are linked to obesity, which must be handled with the aid of obesity management programs. This helps to fuel the adoption of obesity management services and products.
Liraglutide had a notable market share at 32.4%. Liraglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist with a long pharmacokinetic profile that preserves biological activity.
These products promote weight loss by suppressing appetite and energy consumption. GLP-1 receptor agonists can also cause significant weight loss in a short period, which might drive growth in the coming decade.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Gastric sleeve surgery will remain dominant in the market during the forecast period, with an estimated 43.5% market share by the end of 2033. Gastric sleeve surgery is very convenient and safe, with excellent patient outcomes.
This procedure induces hormonal changes to aid in weight loss. These hormones not only help with weight loss but also with high blood pressure and heart disease caused by obesity. It is the simplest methodology and requires less time in surgery.
| Category | By Drug Type |
|---|---|
| Top Segment | Liraglutide |
| Market Share in Percentage | 65.2% |
| Category | By Distribution Channel |
|---|---|
| Top Segment | Hospital Pharmacies |
| Market Share in Percentage | 55.8% |
Hospital pharmacies will account for more than 50% of the global distribution channel. Elevated footfall in hospitals for anti-obesity counseling sessions contributes to a large share of market revenue.
The United States is expected to maintain a high growth rate throughout the forecast period with a total market share of more than 63.0% in 2022. Obesity is a major health issue in the country, resulting in a variety of diseases. North America is expected to generate significant revenue in the global market in the coming years.
Factors like high population awareness, the presence of prominent drug manufacturers, and the rising prevalence of obesity account for the region's rapid growth in this market. The bupropion and naltrexone segment leads the North American market and is likely to sustain its lead, making it highly appealing to stakeholders.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| North America | 35% |
| Europe | 29.5% |
Europe contributes significantly to the overall market's revenue. Obesity in the region is exacerbated by a high intake of processed meats and a high prevalence of lifestyle diseases. The availability of obesity management health programs and government-led obesity management health centers bodes well for the region's obesity management market growth.
Asia Pacific is rapidly emerging as a key market for obesity management. Obesity management programs have emerged as a result of the region's developing countries' excessive rise in obesity incidence as a result of changing lifestyles. This fuels the regional market.
India dominates the South Asian market with a market share of 60.9% and is expected to grow at a CAGR of 4.8%. Rising healthcare expenditures are expected to strengthen the country's market. Obesity among adults is expected to triple between 2010 and 2040, with an estimated 30% of the population being overweight by that time.
Obesity is increasing in the country due to increased consumption of energy-dense foods, a sedentary lifestyle, a lack of health care services, and inadequate financial support.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| The United States | 32.1% |
| Germany | 7% |
| Japan | 4.3% |
Germany held nearly 17.6% of the European market in 2022. The Robert Koch Institute reports that 67% of adults in Germany are overweight. Germany has a significant problem with high cholesterol and type 1 diabetes.
The German federal government is enacting policies to combat the country's growing obesity problem. In addition, the number of anti-obesity clinics in the country has increased. These factors will contribute to the expansion of obesity management in the country.
With a market value of USD 36.6 million in 2022, Russia occupies an important financially rewarding position in Europe. Since 2014, the number of Russians diagnosed with obesity has increased by nearly 50%. According to the WHO, more than 60% of Russians are overweight, with 20% being obese.
The Russian Health Ministry is constantly striving to create strategies for enhancing the population's overall health. According to the World Factbook, the prevalence of adult obesity in Russia is 23.1%.
The regional market in China is expanding at a CAGR of 4.3% and is expected to account for more than 42% of the East Asian market over the forecast period. According to national survey data, more than half of all Chinese adults are now overweight or obese.
Rapid economic growth in the country in recent decades has resulted in significant changes in lifestyle, diet, and exercise habits. According to the National Health Commission report from 2020, more than half of adults are classified as overweight, with 16.4% being obese.
| Regional Markets | CAGR (2023 to 2033) |
|---|---|
| The United Kingdom | 5.1% |
| China | 6.6% |
| India | 6.4% |
| Australia | 4.4% |
Business models evolve sometimes as a result of changes in the obesity management industry, and sometimes as a result of technological advancements, resulting in the emergence of new and exciting market trends.
Standout Market Players You Should Know: Allurion Insights, Apollo Endosurgery, Inc., Obalon Therapeutics, and Glyscend Therapeutics
Launch:
Allurion Insights, a new and powerful addition to the Allurion Virtual Care Suite, was launched today by Allurion Technologies, a pioneering leader in the development of innovative, scalable, and trusted weight loss experiences. Allurion Insights is a weight-loss provider-specific integrated remote patient monitoring and telehealth solution.
Approval:
Apollo Endosurgery, Inc., a leader in minimally invasive endoscopic surgical products for bariatric and gastrointestinal procedures, announced that the US Food and Drug Administration (FDA) has approved the ORBERATM Intragastric Balloon to help adult patients with obesity (BMI 30 to 40) lose and maintain weight.
Approval:
Obalon Therapeutics is making its stock market debut with a USD 75 million IPO to fund the commercialization of its weight loss balloon device in the United States. The product launch comes just a few weeks after Obalon filed for an IPO and revealed that its ingestible weight loss balloon had received FDA PMA approval.
Financing Round:
Glyscend Therapeutics has completed a USD 20.5 million Series A financing round. The round of funding was led by healthcare investors Brandon Capital Partners, through its Medical Research Commercialisation Fund (MRCF), and Santé Ventures, and will be used to support the development of the company's novel oral polymer therapy for patients with T2D and other metabolic diseases. In 2019, Breakout Labs provided seed funding.
The overall market is relatively consolidated, with only a few leading players competing. Humongous players in this market are involved in Research and Development for product innovation and the development of existing products. GlaxoSmithKline Plc, VIVUS, Inc., Novo Nordisk A/S, Currax Pharmaceuticals LLC, Cheplapharm Arzneimittel GmbH, Bausch Health Companies Inc., and Takeda Pharmaceuticals, Inc. are among the prominent companies operating in the global market.
| Date | January 2018 |
|---|---|
| Company Name | H2-Pharma |
| Strategy | Collaboration |
| Details | H2-Pharma announced a collaboration with Cheplapharm Arzneimittel GmbH in January 2018 and re-launched XENICAL® 120 mg capsules through its newly formed branded division. |
| Date | February 2020 |
|---|---|
| Company Name | VIVUS, Inc. |
| Strategy | Collaboration |
| Details | VIVUS, Inc. announced in February 2020 that its Korean marketing partner, Alvogen, had launched Qsymia in the Republic of Korea. |
| Date | June 2021 |
|---|---|
| Company Name | Novo Nordisk |
| Strategy | FDA approval |
| Details | Novo Nordisk received FDA approval for Wegovy semaglutide injection in adults with at least one weight-related condition in June 2021. |
The market is expected to develop a CAGR of 5.2% through 2033.
The market recorded a 4% CAGR from 2018 to 2022.
The market is estimated to secure a valuation of USD 2,095.6 million in 2023.
North America is leading the market, with a share of 35%.
The United States, Japan, and Germany dominate the global market.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type 5.1. Bupropion and Naltrexone 5.2. Orlistat 5.3. Lorcaserin 5.4. Phentermine and Topiramate 5.5. Liraglutide 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Surgery Type 6.1. Gastric Bypass Surgery 6.2. Adjustable Gastric Banding Surgery 6.3. Gastric Sleeve Surgery 6.4. Duodenal Switch Surgery 6.5. Others 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Hospitals Pharmacies 7.2. Retail Pharmacies 7.3. E-commerce 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Western Europe 8.4. Eastern Europe 8.5. South Asia and Pacific 8.6. East Asia 8.7. Middle East and Africa 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. GlaxoSmithKline Plc. 18.2. VIVUS, Inc. 18.3. Novo Nordisk A/S 18.4. Currax Pharmaceuticals LLC 18.5. Cheplapharm Arzneimittel GmbH 18.6. Bausch Health Companies Inc. 18.7. Takeda Pharmaceuticals, Inc. 18.8. Pfizer Inc 18.9. F. Hoffmann-La Roche Ltd 18.10. AstraZeneca 18.11. Herbalife Ltd. 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Obesity Management Market
